Waldenström Macroglobulinemia: The Role of TP53 Mutations in Disease Progression and Therapeutic Response
Emerging evidence suggests that TP53 mutations may have a significant impact on the disease progression and therapeutic response in Waldenström macroglobulinemia.
Waldenström Macroglobulinemia (WM) is a rare, indolent B‑cell lymphoproliferative disorder characterized by the production of monoclonal IgM paraprotein and infiltration of the bone marrow by lymphoplasmacytic cells. While WM generally exhibits a slow clinical course, it has the potential to progress into more aggressive hematologic malignancies, such as diffuse large B‑cell lymphoma. The TP53 gene, often referred to as the the guardian of the genome, plays a pivotal role in maintaining genomic stability, regulating the cell cycle, and orchestrating apoptosis. Mutations in TP53 undermine these essential processes, resulting in dysregulated cellular proliferation, defective apoptotic mechanisms, and genomic instability71 components of cancer development. Although TP53 mutations have been extensively investigated in several hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndromes, and chronic lymphocytic leukemia, their role in WM remains underexplored. Emerging evidence suggests that TP53 mutations may have a significant impact on the disease progression and therapeutic response in WM. This review examines the current knowledge of TP53 mutations in WM, highlighting their implications for prognosis and therapeutic strategies. A deeper understanding of the role of TP53 in WM could provide critical insights for improving disease management and advancing the development of targeted therapies.
Elucidating the role of TP53 mutations in WM is essential for refining prognostic models and guiding personalized therapeutic decisions, potentially improving outcomes in this rare malignancy.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Diffuse Large B‑Cell Lymphoma – Global Clinical Trial Landscape (2024)
- Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
- Mantle‑Cell Lymphoma (MCL)
- Inhibition of autoantigen‑induced B‑cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL)
- Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report